Regenerative Cell Technology Research Constitutes Heart Of MacroPore R&D
This article was originally published in The Gray Sheet
Executive Summary
MacroPore Biosurgery is focusing its R&D dollars on regenerative cell therapy as its biomaterials business struggles to meet expectations
You may also be interested in...
Stem Cell Therapy Needs More Than Just The Cells: Device Firms See Opening
The advent of stem cell therapy to future medicine will be facilitated by medical devices that actually process and store the cells. At least two firms already see near-term opportunities to pioneer the technology
Stem Cell Therapy Needs More Than Just The Cells: Device Firms See Opening
The advent of stem cell therapy to future medicine will be facilitated by medical devices that actually process and store the cells. At least two firms already see near-term opportunities to pioneer the technology
MacroPore regenerates
MacroPore Biosurgery changes name to Cytori Therapeutics in effort to align corporate image with focus on stem cell regenerative therapeutics 1("The Gray Sheet" Aug. 23, 2004, p.14). Cytori's stem cell research concerns therapies for cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. The company will continue to make bioresorbable surgical implants distributed by Medtronic...